> What's not clear is if the referenced antibiotics are all in the long process of approval or if they're considered uneconomical or some other issue. My impres

> What's not clear is if the referenced antibiotics are all in the long process of approval or if they're considered uneconomical or some other issue. My impression was we have a strong need for approved treatments for resistant bacteria, given the way the problem is talked about in the media. I would have expected there'd be a market for them at some price that works. The reason novel antibiotics are not profitable is because we specifically DON'T want to use them. These novel antibiotics become fourth, fifth, sixth line treatments. And that's after probably retrying the previous line for multiple rounds at bigger dosages, or in combination therapy. So in reality, that means that drug companies are not set to make a lot of money on them. Most of the novel antibiotic development funding comes directly from the government. And even that is being cut.